Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” | The company benefited from higher-than-expected sales of ...
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...
Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.
Drugmaker pauses HPV Gardasil exports as rival Pfizer gets boost from better than expected Covid vaccine and pill sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback